High Prevalence of Lash Collarettes in Patients with Atopic Dermatitis Treated with Dupilumab

Kychygina A, Cassagne M, Tauber M, Galiacy S, Paul C, Fournié P, et al. Dupilumab-associated adverse events during treatment of allergic diseases. Clin Rev Allergy Immunol 2022; 62: 519–533. DOI: https://doi.org/10.1007/s12016-022-08934-0

Fachler T, Shreberk-Hassidim R, Molho-Pessach V. Dupilumab-induced ocular surface disease: a systematic review. J Am Acad Dermatol 2022; 86: 486–487. DOI: https://doi.org/10.1016/j.jaad.2021.09.029

Achten R, Thijs J, van der Wal M, van Luijk C, de Graaf M, Bakker D, et al. Dupilumab-associated ocular surface disease in atopic dermatitis patients: clinical characteristics, ophthalmic treatment response and conjunctival goblet cell analysis. Allergy 2023; 78: 2266–2276. DOI: https://doi.org/10.1111/all.15717

Serino F, Dattilo V, Cennamo M, Roszkowska AM, Gola M, Magliulo M, et al. Dupilumab-associated blepharoconjunctivitis: clinical and morphological aspects. Biomedicines 2023; 11: 3104. DOI: https://doi.org/10.3390/biomedicines11123104

Hanifin JM, Thurston M, Omoto M, Cherill R, Tofte SJ, Graeber M. The Eczema Area and Severity Index (EASI): assessment of reliability in atopic dermatitis. Exp Dermatol 2001; 10: 11–18. DOI: https://doi.org/10.1034/j.1600-0625.2001.100102.x

Finlay AY, Khan GK. Dermatology Life Quality Index (DLQI) – a simple practical measure for routine clinical use. Clin Exp Dermatol 1994; 19: 210–216. DOI: https://doi.org/10.1111/j.1365-2230.1994.tb01167.x

Schulze MM, Hutchings N, Simpson TL. The use of fractal analysis and photometry to estimate the accuracy of bulbar redness grading scales. Invest Ophthalmol Vis Sci 2008; 49: 1398–1406. DOI: https://doi.org/10.1167/iovs.07-1306

Yeu EL, Wirta DL, Karpecki P, Baba SN, Holdbrook M, Saturn I Study Group. Lotilaner ophthalmic solution, 0.25%, for the treatment of demodex blepharitis: results of a prospective, randomized, vehicle-controlled, double-masked, pivotal trial (Saturn-1). Cornea 2023; 42: 435–443. DOI: https://doi.org/10.1097/ICO.0000000000003097

Tappeiner C, Heiligenhaus A, Halter JP, Miserocchi E, Bandello F, Goldblum D. Challenges and concepts in the diagnosis and management of ocular graft-versus-host disease. Front Med (Lausanne) 2023; 10: 1133381. DOI: https://doi.org/10.3389/fmed.2023.1133381

Anh BTV, Thuy PT, Ngoc NTB, Hien NTT, Yen PH, Quyet D, et al. Dry eyes status on Des scale and related factors in outpatients at Vietnam National Institute of Ophthalmology. Open Access Maced J Med Sci 2019; 7: 4292–4296. DOI: https://doi.org/10.3889/oamjms.2019.377

Rhee MK, Yeu E, Barnett M, Rapuano CJ, Dhaliwal DK, Nichols KK, et al. Demodex blepharitis: a comprehensive review of the disease, current management, and emerging therapies. Eye Contact Lens 2023; 49: 311–318. DOI: https://doi.org/10.1097/ICL.0000000000001003

Thyssen JP. Could conjunctivitis in patients with atopic dermatitis treated with dupilumab be caused by colonization with Demodex and increased interleukin-17 levels? Br J Dermatol 2018; 178: 1220. DOI: https://doi.org/10.1111/bjd.16330

Ricardo-Gonzalez RR, Kotas ME, O’Leary CE, Singh K, Damsky W, Liao C, et al. Innate type 2 immunity controls hair follicle commensalism by Demodex mites. Immunity 2022; 55: 1891–1908.e12. DOI: https://doi.org/10.1016/j.immuni.2022.08.001

Smith PC, Zeiss CJ, Beck AP, Scholz JA. Demodex musculi infestation in genetically immunomodulated mice. Comp Med 2016; 66: 278–285.

McCann P, Abraham AG, Mukhopadhyay A, Panagiotopoulou K, Chen H, Rittiphairoj T, et al. Prevalence and incidence of dry eye and meibomian gland dysfunction in the united states: a systematic review and meta-analysis, JAMA Ophthalmol 2022; 140: 1181–1192. DOI: https://doi.org/10.1001/jamaophthalmol.2022.4394

Marolo P, Ribero S, Caselgrandi P, Ghilardi A, de Sanctis U, Parisi G, et al. Ocular surface disease in patients with atopic dermatitis treated with dupilumab: a prospective case-control study. Cornea 2024; 43: 221–227. DOI: https://doi.org/10.1097/ICO.0000000000003341